# Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

> **NCT05733689** · PHASE1 · RECRUITING · sponsor: **University of California, Irvine** · enrollment: 20 (estimated)

## Conditions studied

- Gastroesophageal Adenocarcinoma

## Interventions

- **COMBINATION_PRODUCT:** FLOT
- **COMBINATION_PRODUCT:** FOLFOX
- **COMBINATION_PRODUCT:** FOLFIRI
- **COMBINATION_PRODUCT:** FOLFIRINOX
- **COMBINATION_PRODUCT:** PACLITAXEL with or without CARBOPLATIN
- **COMBINATION_PRODUCT:** DOCETAXEL and IRINOTECAN (alone or combined)
- **DRUG:** NIVOLUMAB (alone or when added to a regimen above)
- **DRUG:** PEMBROLIZUMAB (alone or when added to a regimen above)
- **DRUG:** Durvalumab
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT05733689
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-27
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05733689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05733689, "Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05733689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*